Last reviewed · How we verify
EN3270
EN3270 is a small molecule that targets the sigma-1 receptor.
EN3270 is a small molecule that targets the sigma-1 receptor. Used for Chronic pain.
At a glance
| Generic name | EN3270 |
|---|---|
| Sponsor | Durect |
| Drug class | sigma-1 receptor agonist |
| Target | sigma-1 receptor |
| Modality | Small molecule |
| Therapeutic area | Pain |
| Phase | Phase 2 |
Mechanism of action
EN3270 works by binding to the sigma-1 receptor, which is involved in various cellular processes. This binding leads to a cascade of downstream effects that ultimately result in the therapeutic effect of the drug.
Approved indications
- Chronic pain
Common side effects
- Nausea
- Headache
- Dizziness
Key clinical trials
- Open Label, Safety Study of EN3270 in Patients With Moderate to Severe Non-malignant, Chronic Pain (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- EN3270 CI brief — competitive landscape report
- EN3270 updates RSS · CI watch RSS
- Durect portfolio CI